"Their effects on vaginal health are an important consideration that is often overlooked," gynecologist Melanie Bone told Newsweek.

Annie Dalby, 47, had previously found herself in the 'obese' BMI category and struggled to lose weight. However, she has now ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

Divi’s Laboratories share price rose 12.02% this week, driven by Citi Research’s ’buy’ rating and a target price of ₹6,400.

Comorbid diabetes was linked to worse functional and mortality outcomes, including maximum oxygen consumption, among patients with heart failure.

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they ...

While employers footed the bill for health plan price increases in 2024, they were largely unwilling to give employees access ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Kelly Osbourne once made her feelings on Ozempic very clear following her mum Sharon’s admission about the medication ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.